Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study
Sleep Medicine · 2025
DOI: 10.1016/j.sleep.2025.106704 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sleep Medicine, 2025. Verfasst von Jingjing Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhenjiang Mental Health Center, No.199, Tuanshan Road, Zhenjiang, Jiangsu, 212001, China. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Transcranial Magnetic Stimulation, Prefrontal Cortex. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Science and Technology Bureau of Zhenjiang.
Themen: Schlaf
Abstract (Originalsprache)
BACKGROUND: Medial prefrontal cortex (mPFC) may play an important role in the pathophysiological mechanism of insomnia and may be a potential target for treating insomnia. Herein, we aimed to investigate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) for chronic insomnia. METHODS: We conducted a pilot, double-blind, randomized, sham-controlled trial. 62 participants with chronic insomnia were recruited and randomly allocated to either the active or sham rTMS group. Forty-one patients completed 20 sessions of active or sham intervention targeting the mPFC and assessments at baseline, end of intervention, and follow-up. RESULTS: After 4-week intervention, the response rate and remission rate were significantly higher in the active group (51.7 % and 44.8 %) than those in the sham group (20.8 % and 16.7 %), with p = 0.037 and p = 0.048, respectively. At 4-week follow-up, the response rate and remission rate were not different between groups. There were significant interaction between group and time for insomnia severity using Pittsburgh Sleep Quality Index (PSQI) and sleep onset latency, daily disturbances, and hypnotic drug use. Post hoc analysis revealed that, compared with the sham group, the active group showed significant improvements in insomnia symptoms (except for total sleep time and sleep efficiency) at the end of the 4-week intervention, and significant improvements in PSQI scores, sleep onset latency, sleep efficiency, daily disturbances and hypnotic drug use at the 4-week follow-up. There were no statistically significant difference in adverse events between the two groups, and there were no serious adverse events occurred during treatment. CONCLUSION: mPFC-rTMS maybe an effective and safety therapeutic in chronic insomnia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhenjiang Mental Health Center, No.199, Tuanshan Road, Zhenjiang, Jiangsu, 212001, China.
- Zhenjiang Mental Health Center, No.199, Tuanshan Road, Zhenjiang, Jiangsu, 212001, China. Electronic address: 910570288@qq.com.
Förderung
- Science and Technology Bureau of Zhenjiang
Zitieren
APA
Sun, J., Li, P., Yi, Y., Xu, W., Zhang, G., Zhang, B., Ding, K., Luo, S., & Zhou, J. (2025). Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.106704
Vancouver
Sun J, Li P, Yi Y, Xu W, Zhang G, Zhang B, et al. Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.106704
BibTeX
@article{Sun2025,
author = {Sun, Jingjing and Li, Panpan and Yi, Yun and Xu, Wenyue and Zhang, Guanghua and Zhang, Bidan and Ding, Kaimo and Luo, Si and Zhou, Juanjuan},
title = {Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study},
journal = {Sleep Medicine},
year = {2025},
doi = {10.1016/j.sleep.2025.106704}
}
EUVIMED